Boston Scientific (BSX) amended the recall of its Accolade pacemakers again, updating the software further and expanding the affected population to 1.6 million people, the New York Times reported Thursday, citing company documents and filings.

The latest recall includes newer devices including "dual chamber" pacemakers and "cardiac resynchronization" pacemakers. Boston Scientific said these devices have a 7.6% chance of needing early replacement because they might encounter a high impedance battery issue at some point, The New York Times added.

The company said the software update effectively mitigates the risk of Safety Mode, but patients must visit their doctors to benefit from the update, according to the report.

Boston Scientific did not immediately respond to a request for comment by MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 70.39, Change: -0.89, Percent Change: -1.25